sur Pentixapharm Holding AG (isin : DE000A40AEG0)
Nuclear Medicine Expert Ken Herrmann Joins Pentixapharm's Board
Prof. Dr. Ken Herrmann has officially joined the Supervisory Board of Pentixapharm Holding AG, as announced on October 28, 2024. Herrmann, renowned in the field of nuclear medicine, is also the Head of the Department of Nuclear Medicine at Universitätsklinikum Essen in Germany. His appointment was agreed upon at a shareholder meeting in June 2024, but administrative delays postponed his involvement.
Dr. Andreas Eckert, Executive Chairman of Pentixapharm, expressed enthusiasm for Herrmann's addition. Herrmann's expertise in radiopharmaceuticals is expected to bolster the company's oncology pipeline, which focuses on non-Hodgkin lymphomas treatment and diagnostics through Y90-PentixaTher and Ga68-PentixaFor.
Herrmann brings considerable expertise, having served previously as the Chair of the European Association of Nuclear Medicine's Oncology & Theranostics Committee. He is also a prolific researcher and an established academic presence, further complementing his new role at Pentixapharm.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pentixapharm Holding AG